• linkedin
  • Increase Font
  • Sharebar

    Liver distress: Top 10 care and cost concerns




    Patients infected with hepatitis C virus (HCV) are at high risk for the development of liver cirrhosis or liver cancer. Early detection and treatment, particularly with new direct-acting antiviral (DAA) therapies, are the keys to improved outcomes. But high costs and insurance issues continue to limit access to both diagnosis and treatment for many patients.

    In our hepatology coverage this year, Medical Economics chronicled the main issues, new studies, and treatment advances that impact our readers’ business and clinical practice. Click through the slides (above/below) for a quick review of efforts to remove obstacles to optimal care for patients infected with HCV.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow